The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis
NCT06546540
·
clinicaltrials.gov ↗
PHASE4
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Systemic Sclerosis
Interventions
DRUG:
Telitacicept
Sponsor
Peking University Third Hospital